NU Skin Enterprises market cap NUS
Share price times shares outstanding: what the whole company sells for, since 2010.
- Today, Oct 23, 2026
- $233.2M
- Highest close in our data
- $8.2B
- Jan 2014
NU Skin Enterprises is worth $233.2M at the close on Oct 23, 2026, at $4.79 a share.
That is down 57% over the last year and down 88% over five years.
Its highest close in our data was $8.2B in Jan 2014.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $233.2M | $222.9M | $562.6M | −51% |
| 2025 | $479.7M | $272.5M | $605.9M | +43% |
| 2024 | $336M | $306.2M | $926.9M | −65% |
| 2023 | $959.5M | $816.2M | $2.2B | −54% |
| 2022 | $2.1B | $1.7B | $2.7B | −18% |
| 2021 | $2.5B | $2B | $3.1B | −9% |
| 2020 | $2.8B | $1.1B | $2.9B | +24% |
| 2019 | $2.3B | $2.1B | $3.7B | −32% |
| 2018 | $3.3B | $3.2B | $4.7B | −7% |
| 2017 | $3.6B | $2.6B | $3.7B | +38% |
| 2016 | $2.6B | $1.6B | $3.6B | +20% |
| 2015 | $2.2B | $1.9B | $3.6B | −21% |
| 2014 | $2.7B | $2.3B | $8.2B | −67% |
| 2013 | $8.1B | $2.2B | $8.1B | +293% |
| 2012 | $2.1B | $2B | $3.8B | −31% |
| 2011 | $3B | $1B | $3.1B | +61% |
| 2010 | $1.9B | $1.9B | $2B | n/a |
Against its peers
Companies in Healthcare nearest NU Skin Enterprises' size, closest first, today.
| Company | Market cap |
|---|---|
| NUSNU Skin Enterprises | $233.2M |
| UTMDUtah Medical Products | $236.3M |
| ELMDElectromed | $220.6M |
| NATRNatures Sunshine Products | $213.8M |
| PLXProtalix BioTherapeutics | $205.5M |
| PDEXPro DEX | $199.3M |
| INFUInfuSystem | $277.6M |
| VMDViemed Healthcare | $373.3M |
| EMBCEmbecta | $380.2M |
| ARVNArvinas | $477.3M |
| NRCNRC Health | $485.1M |
| Peer median | $257M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on NU Skin Enterprises
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.